Search

Your search keyword '"Hagge, Deanna"' showing total 167 results
Start Over Author "Hagge, Deanna"
167 results on '"Hagge, Deanna"'

1. The Many Hosts of Mycobacteria 9 (MHM9): A conference report

Author

Klever, Abigail Marie, Alexander, Kathleen A., Almeida, Deepak, Anderson, Matthew Z., Ball, Ray L., Beamer, Gillian, Boggiatto, Paola, Buikstra, Jane E., Chandler, Bruce, Claeys, Tiffany A., Concha, Aislinn E., Converse, Paul J., Derbyshire, Keith M., Dobos, Karen M., Dupnik, Kathryn M., Endsley, Janice J., Endsley, Mark A., Fennelly, Kevin, Franco-Paredes, Carlos, Hagge, Deanna A., Hall-Stoodley, Luanne, Hayes, Don, Jr., Hirschfeld, Katherine, Hofman, Courtney A., Honda, Jennifer R., Hull, Natalie M., Kramnik, Igor, Lacourciere, Karen, Lahiri, Ramanuj, Lamont, Elise A., Larsen, Michelle H., Lemaire, Timothy, Lesellier, Sandrine, Lee, Naomi R., Lowry, Christopher A., Mahfooz, Najmus S., McMichael, Temet M., Merling, Marlena R., Miller, Michele A., Nagajyothi, Jyothi F., Nelson, Elizabeth, Nuermberger, Eric L., Pena, Maria T., Perea, Claudia, Podell, Brendan K., Pyle, Charlie J., Quinn, Fred D., Rajaram, Murugesan V.S., Mejia, Oscar Rosas, Rothoff, Michelle, Sago, Saydie A., Salvador, Liliana C.M., Simonson, Andrew W., Spencer, John S., Sreevatsan, Srinand, Subbian, Selvakumar, Sunstrum, James, Tobin, David M., Vijayan, K.K.Vidya, Wright, Caelan T.O., and Robinson, Richard T.

Published
2023
Full Text
View/download PDF

4. Evaluation of a self-help intervention to promote the health and wellbeing of marginalised people including those living with leprosy in Nepal: a prospective, observational, cluster-based, cohort study with controls

Author

Shrestha, Dilip, Napit, Indra B., Ansari, Subi, Choudhury, Sopna Mannan, Dhungana, Bishnu, Gill, Paramjit, Griffiths, Frances, Gwyther, Holly, Hagge, Deanna, Kandel, Shovakhar, Puri, Suraj, Sartori, Jo, Watson, Samuel Ian, and Lilford, Richard

Published
2021
Full Text
View/download PDF

5. Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study

Author

Tió-Coma, Maria, van Hooij, Anouk, Bobosha, Kidist, van der Ploeg-van Schip, Jolien J., Banu, Sayera, Khadge, Saraswoti, Thapa, Pratibha, Kunwar, Chhatra B., Goulart, Isabela M., Bekele, Yonas, Hagge, Deanna A., Moraes, Milton O., Teles, Rosane M. B., Pinheiro, Roberta Olmo, van Zwet, Erik W., Goeman, Jelle J., Aseffa, Abraham, Haks, Mariëlle C., Ottenhoff, Tom H. M., Modlin, Robert L., and Geluk, Annemieke

Published
2019
Full Text
View/download PDF

7. Utility of a Mycobacterium leprae molecular viability assay for clinical leprosy: An analysis of cases from the Philippines, Ethiopia, and Nepal

Author

Lenz, Shannon M., primary, Ray, Nashone A., additional, Lema, Tsehaynesh, additional, Collins, J. Hunter, additional, Thapa, Ruby, additional, Girma, Selfu, additional, Balagon, Marivic, additional, Bobosha, Kidist, additional, Hagge, Deanna A., additional, Williams, Diana L., additional, Scollard, David M., additional, Lahiri, Ramanuj, additional, and Adams, Linda B., additional

Published
2022
Full Text
View/download PDF

13. Prednisolone adverse events in the treatment and prevention of leprosy neuropathy in two large double blind randomized clinical trials

Author

Post, Erik, primary, Wagenaar, Inge, additional, Brandsma, Wim, additional, Bowers, Bob, additional, Alam, Khorshed, additional, Shetty, Vanaja, additional, Pai, Vivek, additional, Husain, Sajid, additional, Prakoeswa, Cita Rosita Sigit, additional, Astari, Linda, additional, Hagge, Deanna, additional, Shah, Mahesh, additional, Neupane, Kapil, additional, Lama, Krishna, additional, Nicholls, Peter, additional, and Hendrik Richardus, Jan, additional

Published
2021
Full Text
View/download PDF

14. Prednisolone adverse events in the treatment and prevention of leprosy neuropathy in two large double blind randomized clinical trials

Author

Post, Erik, Wagenaar, Inge, Brandsma, Wim, Bowers, Bob, Alam, Khorshed, Shetty, Vanaja, Pai, Vivek, Husain, Sajid, Prakoeswa, Cita Rosita Sigit, Astari, Linda, Hagge, Deanna, Shah, Mahesh, Neupane, Kapil, Lama, Krishna, Nicholls, Peter, Richardus, Jan Hendrik, Post, Erik, Wagenaar, Inge, Brandsma, Wim, Bowers, Bob, Alam, Khorshed, Shetty, Vanaja, Pai, Vivek, Husain, Sajid, Prakoeswa, Cita Rosita Sigit, Astari, Linda, Hagge, Deanna, Shah, Mahesh, Neupane, Kapil, Lama, Krishna, Nicholls, Peter, and Richardus, Jan Hendrik

Abstract

Objectives To document serious adverse events (SAE) of prolonged prednisolone use in two double-blind randomized clinical trials (RCT). In the first RCT, treatment effectiveness on restoring nerve function of a 20-week prednisolone regimen was compared with a 32-week course. In the second RCT, patients with subclinical neuropathy received either 20 weeks prednisolone or placebo to assess whether prednisolone could prevent the development of clinical neuropathy. In both trials, patients received a prednisolone starting dose according to weight: high weight (≥50 kg) started at 60 mg and low weight (<50 kg) at 45 mg. In both trials, the occurrence of serious adverse events (SAE) was an important secondary outcome. Results In the first RCT, 868 patients were enrolled, of whom 16 (1.8%) developed a serious adverse event (SAE). There were 12 SAEs in the longer treatment arm (N = 439, event rate of 2.7%), and four in the shorter arm (N = 429, event rate of 0.9%) (p = 0.041). In the second RCT 4/364 (1.1%) developed an SAE, of which one was in the placebo arm. In both trials, minor adverse events were quite common and varied greatly in frequency and between centres. Conclusions When searching for the optimum dose and duration of prednisolone in the treatment and prevention of neuropathy in leprosy patients, one must weigh possible advantages against the possible serious adverse events. Although our trials showed a significantly increased percentage of SAE in the longer treatment arm in the first RCT and in the treatment arm of the second RCT, the overall event rate was very low.

Published
2021

15. Additional file 1 of Evaluation of a self-help intervention to promote the health and wellbeing of marginalised people including those living with leprosy in Nepal: a prospective, observational, cluster-based, cohort study with controls

Author

Shrestha, Dilip, Napit, Indra B., Ansari, Subi, Sopna Mannan Choudhury, Bishnu Dhungana, Gill, Paramjit, Griffiths, Frances, Gwyther, Holly, Hagge, Deanna, Shovakhar Kandel, Puri, Suraj, Sartori, Jo, Watson, Samuel Ian, and Lilford, Richard

Abstract

Additional file 1. Consumption Questionnaire. Description: A consumption questionnaire derived from Sections 2, 5, 6 and 7 of the Nepal: Living Standards Survey (NLSS: 2011/12) in order to measure economic status.

Published
2021
Full Text
View/download PDF

16. Additional file 2 of Evaluation of a self-help intervention to promote the health and wellbeing of marginalised people including those living with leprosy in Nepal: a prospective, observational, cluster-based, cohort study with controls

Author

Shrestha, Dilip, Napit, Indra B., Ansari, Subi, Sopna Mannan Choudhury, Bishnu Dhungana, Gill, Paramjit, Griffiths, Frances, Gwyther, Holly, Hagge, Deanna, Shovakhar Kandel, Puri, Suraj, Sartori, Jo, Watson, Samuel Ian, and Lilford, Richard

Subjects
genetic structures, eye diseases
Abstract

Additional file 2. Clinical Data Collection Form (Patients at Risk of Ulcer Sub-Group). Description: Standard clinical data collection form used by researchers in Nepal to describe condition of patients’ limbs and eyes.

Published
2021
Full Text
View/download PDF

17. Additional file 3 of Evaluation of a self-help intervention to promote the health and wellbeing of marginalised people including those living with leprosy in Nepal: a prospective, observational, cluster-based, cohort study with controls

Author

Shrestha, Dilip, Napit, Indra B., Ansari, Subi, Sopna Mannan Choudhury, Bishnu Dhungana, Gill, Paramjit, Griffiths, Frances, Gwyther, Holly, Hagge, Deanna, Shovakhar Kandel, Puri, Suraj, Sartori, Jo, Watson, Samuel Ian, and Lilford, Richard

Abstract

Additional file 3. Statistical Model. Description: Calculations regarding the precision of the measurement of the effect size of the intervention.

Published
2021
Full Text
View/download PDF

18. An assessment of the reported impact of the COVID-19 pandemic on leprosy services using an online survey of practitioners in leprosy referral centres

Author

de Barros, Barbara, primary, Lambert, Saba M, additional, Negera, Edessa, additional, de Arquer, Guillermo Robert, additional, Sales, Anna M, additional, Darlong, Joydeepa, additional, Dias, Vivianne L A, additional, Rozario, Benjamin Jewel, additional, Pai, Vivek V, additional, Alinda, Medhi Denisa, additional, Listiawan, M Yulianto, additional, Hagge, Deanna A, additional, Shah, Mahesh, additional, Lockwood, Diana N J, additional, and Walker, Stephen L, additional

Published
2021
Full Text
View/download PDF

19. An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol

Author

Napit, Indra B, primary, Shrestha, Dilip, additional, Bishop, Jon, additional, Choudhury, Sopna, additional, Dulal, Santosh, additional, Gill, Paramjit Singh, additional, Gkini, Eleni, additional, Gwyther, Holly E, additional, Hagge, Deanna A, additional, Neupane, Karuna, additional, Sartori, Jo, additional, Slinn, Gemma, additional, Watson, Samuel L, additional, and Lilford, Richard, additional

Published
2021
Full Text
View/download PDF

20. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial

Author

de Barros, Barbara, primary, Lambert, Saba M, additional, Shah, Mahesh, additional, Pai, Vivek V, additional, Darlong, Joydeepa, additional, Rozario, Benjamin Jewel, additional, Alinda, Medhi Denisa, additional, Sales, Anna M, additional, Doni, Shimelis, additional, Hagge, Deanna A, additional, Shrestha, Dilip, additional, Listiawan, M. Yulianto, additional, Yitaye, Abeba M, additional, Nery, Jose A C, additional, Neupane, Kapil D, additional, Dias, Vivianne L A, additional, Butlin, C. Ruth, additional, Nicholls, Peter G, additional, Lockwood, Diana, additional, and Walker, Stephen L, additional

Published
2020
Full Text
View/download PDF

22. Identification of a systemic interferon-γ inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction

Author

Teles, Rosane M. B., primary, Lu, Jing, additional, Tió-Coma, Maria, additional, Goulart, Isabela M. B., additional, Banu, Sayera, additional, Hagge, Deanna, additional, Bobosha, Kidist, additional, Ottenhoff, Tom H. M., additional, Pellegrini, Matteo, additional, Geluk, Annemieke, additional, and Modlin, Robert L., additional

Published
2019
Full Text
View/download PDF

23. assessment of the reported impact of the COVID-19 pandemic on leprosy services using an online survey of practitioners in leprosy referral centres.

Author

Barros, Barbara de, Lambert, Saba M, Negera, Edessa, Arquer, Guillermo Robert de, Sales, Anna M, Darlong, Joydeepa, Dias, Vivianne L A, Rozario, Benjamin Jewel, Pai, Vivek V, Alinda, Medhi Denisa, Listiawan, M Yulianto, Hagge, Deanna A, Shah, Mahesh, Lockwood, Diana N J, and Walker, Stephen L

Subjects
COVID-19 pandemic, COVID-19, HANSEN'S disease, NEGLECTED diseases, MEDICAL personnel
Abstract

Background The coronavirus disease 2019 (COVID-19) pandemic has led to governments implementing a variety of public health measures to control transmission and has affected health services. Leprosy is a communicable neglected tropical disease caused by Mycobacterium leprae and is an important health problem in low- and middle-income countries. The natural history of leprosy means that affected individuals need long-term follow-up. The measures recommended to reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can create barriers to health services. We evaluated the impact of the COVID-19 epidemic response on leprosy services and disease management. Methods We conducted a cross-sectional online survey with healthcare professionals in leprosy referral centres. Results Eighty percent of leprosy diagnostic services were reduced. All respondents reported that multidrug therapy (MDT) was available but two reported a reduced stock. Clinicians used alternative strategies such as telephone consultations to maintain contact with patients. However, patients were not able to travel to the referral centres. Discussion This study highlights the effects of the initial phase of the SARS-CoV-2 pandemic on leprosy services in a range of leprosy-endemic countries. Many services remained open, providing leprosy diagnosis, MDT and leprosy reaction medications. Centres developed innovative measures to counter the negative impacts of the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale

Author

Walker, Stephen L, Sales, Anna M, Butlin, C Ruth, Shah, Mahesh, Maghanoy, Armi, Lambert, Saba M, Darlong, Joydeepa, Rozario, Benjamin Jewel, Pai, Vivek V, Balagon, Marivic, Doni, Shimelis N, Hagge, Deanna A, Nery, José AC, Neupane, Kapil D, Baral, Suwash, Sangma, Biliom A, Alembo, Digafe T, Yetaye, Abeba M, Hassan, Belaynesh A, Shelemo, Mohammed B, Nicholls, Peter G, Lockwood, Diana NJ, and Erythema Nodosum Leprosum International STudy Group

Subjects
Bacterial Diseases, Male, Medical Doctors, Health Care Providers, Pathology and Laboratory Medicine, Severity of Illness Index, Geographical Locations, 030207 dermatology & venereal diseases, 0302 clinical medicine, Erythema Nodosum, Medicine and Health Sciences, Young adult, Immune Response, Musculoskeletal System, health care economics and organizations, Bangladesh, lcsh:Public aspects of medicine, Middle Aged, Leprosy, Lepromatous, Erythema nodosum leprosum, Professions, Infectious Diseases, Scale (social sciences), Female, Leprosy, Anatomy, Research Article, Neglected Tropical Diseases, Adult, medicine.medical_specialty, lcsh:Arctic medicine. Tropical medicine, Asia, lcsh:RC955-962, 030231 tropical medicine, Immunology, MEDLINE, India, macromolecular substances, Dermatology, 03 medical and health sciences, Young Adult, Signs and Symptoms, Cronbach's alpha, Diagnostic Medicine, Physicians, Severity of illness, medicine, Humans, Inflammation, Receiver operating characteristic, business.industry, Public Health, Environmental and Occupational Health, Biology and Life Sciences, lcsh:RA1-1270, medicine.disease, Tropical Diseases, Health Care, Joints (Anatomy), Erythema, People and Places, Physical therapy, Lesions, Population Groupings, business
Abstract

Objectives We wished to validate our recently devised 16-item ENLIST ENL Severity Scale, a clinical tool for measuring the severity of the serious leprosy associated complication of erythema nodosum leprosum (ENL). We also wished to assess the responsiveness of the ENLIST ENL Severity Scale in detecting clinical change in patients with ENL. Methods Participants, recruited from seven centres in six leprosy endemic countries, were assessed using the ENLIST ENL Severity Scale by two researchers, one of whom categorised the severity of ENL. At a subsequent visit a further assessment using the scale was made and both participant and physician rated the change in ENL using the subjective categories of “Much better”, “somewhat better”, “somewhat worse” and “much worse” compared with “No change” or “about the same”. Results 447 participants were assessed with the ENLIST ENL Severity Scale. The Cronbach alpha of the scale and each item was calculated to determine the internal consistency of the scale. The ENLIST ENL Severity Scale had good internal consistency and this improved following removal of six items to give a Cronbach’s alpha of 0.77. The cut off between mild ENL and more severe disease was 9 determined using ROC curves. The minimal important difference of the scale was determined to be 5 using both participant and physician ratings of change. Conclusions The 10-item ENLIST ENL Severity Scale is the first valid, reliable and responsive measure of ENL severity and improves our ability to assess and compare patients and their treatments in this severe and difficult to manage complication of leprosy. The ENLIST ENL Severity Scale will assist physicians in the monitoring and treatment of patients with ENL. The ENLIST ENL Severity Scale is easy to apply and will be useful as an outcome measure in treatment studies and enable the standardisation of other clinical and laboratory ENL research., Author summary Erythema nodosum leprosum (ENL) is a severe, painful complication of leprosy, which can occur before, during or after successful treatment of the infection. ENL is characterised by severe pain and the development of new painful skin lesions. Other organ systems are often affected. ENL may continue to affect people for many years leading to disability, significant loss of income and sometimes death. ENL often requires prolonged treatment with corticosteroids, thalidomide or other drugs that modulate the immune system. Thalidomide is the most effective treatment but is not widely available or affordable in many leprosy endemic settings. This results in many people taking high doses of corticosteroids for prolonged periods and being at risk of severe adverse effects. In order to assess the efficacy of different treatments for ENL it is important to be able to compare individuals before and after treatment. This is difficult to do in a complex, multi-system disorder such as ENL. To overcome this problem we have developed a scale, which is easy to use, to measure the severity of ENL. In this article, we describe the validation of this scale, which ensures that it is a useful measure of ENL severity.

Published
2017

27. Exploratory urinary metabolomics of type 1 leprosy reactions

Author

Mayboroda, Oleg. A., primary, van Hooij, Anouk, additional, Derks, Rico, additional, van den Eeden, Susan J.F., additional, Dijkman, Karin, additional, Khadge, Saraswoti, additional, Thapa, Pratibha, additional, Kunwar, Chhatra B., additional, Hagge, Deanna A., additional, and Geluk, Annemieke, additional

Published
2016
Full Text
View/download PDF

30. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal

Author

Khadge, Saraswoti, primary, Banu, Sayera, additional, Bobosha, Kidist, additional, van der Ploeg-van Schip, Jolien J., additional, Goulart, Isabela M., additional, Thapa, Pratibha, additional, Kunwar, Chhatra B., additional, van Meijgaarden, Krista E., additional, van den Eeden, Susan J.F., additional, Wilson, Louis, additional, Kabir, Senjuti, additional, Dey, Hymonti, additional, Goulart, Luiz R., additional, Lobato, Janaina, additional, Carvalho, Washington, additional, Bekele, Yonas, additional, Franken, Kees L.M.C., additional, Aseffa, Abraham, additional, Spencer, John S., additional, Oskam, Linda, additional, Otttenhoff, Tom H.M., additional, Hagge, Deanna A., additional, and Geluk, Annemieke, additional

Published
2015
Full Text
View/download PDF

32. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.

Author

Wagenaar, Inge, Post, Erik, Brandsma, Wim, Bowers, Bob, Alam, Khorshed, Shetty, Vanaja, Pai, Vivek, Husain, Sajid, Sigit Prakoeswa, Cita Rosita, Astari, Linda, Hagge, Deanna, Shah, Mahesh, Neupane, Kapil, Tamang, Krishna Bahadur, Null, Null, Nicholls, Peter, and Richardus, Jan Hendrik

Subjects
HANSEN'S disease treatment, CHEMOTHERAPY-related cognitive impairment, HANSEN'S disease patients, PREDNISOLONE, NEUROPATHY, DISEASES, THERAPEUTICS
Abstract

Background: While prednisolone is commonly used to treat recent nerve function impairment (NFI) in leprosy patients, the optimal treatment duration has not yet been established. In this “Treatment of Early Neuropathy in Leprosy” (TENLEP) trial, we evaluated whether a 32-week prednisolone course is more effective than a 20-week course in restoring and improving nerve function. Methods: In this multi-centre, triple-blind, randomized controlled trial, leprosy patients who had recently developed clinical NFI (<6 months) were allocated to a prednisolone treatment regimen of either 20 weeks or 32 weeks. Prednisolone was started at either 45 or 60 mg/day, depending on the patient’s body weight, and was then tapered. Throughout follow up, NFI was assessed by voluntary muscle testing and monofilament testing. The primary outcome was the proportion of patients with improved or restored nerve function at week 78. As secondary outcomes, we analysed improvements between baseline and week 78 on the Reaction Severity Scale, the SALSA Scale and the Participation Scale. Serious Adverse Events and the need for additional prednisolone treatment were monitored and reported. Results: We included 868 patients in the study, 429 in the 20-week arm and 439 in the 32-week arm. At 78 weeks, the proportion of patients with improved or restored nerve function did not differ significantly between the groups: 78.1% in the 20-week arm and 77.5% in the 32-week arm (p = 0.821). Nor were there any differences in secondary outcomes, except for a significant higher proportion of Serious Adverse Events in the longer treatment arm. Conclusion: In our study, a 20-week course of prednisolone was as effective as a 32-week course in improving and restoring recent clinical NFI in leprosy patients. Twenty weeks is therefore the preferred initial treatment duration for leprosy neuropathy, after which likely only a minority of patients require further individualized treatment. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Safety and Efficacy Assessment of Two New Leprosy Skin Test Antigens: Randomized Double Blind Clinical Study

Author

Rivoire, Becky L., primary, Groathouse, Nathan A., additional, TerLouw, Stephen, additional, Neupane, Kapil Dev, additional, Ranjit, Chaman, additional, Sapkota, Bishwa Raj, additional, Khadge, Saraswoti, additional, Kunwar, Chatra B., additional, Macdonald, Murdo, additional, Hawksworth, Rachel, additional, Thapa, Min B., additional, Hagge, Deanna A., additional, Tibbals, Melinda, additional, Smith, Carol, additional, Dube, Tina, additional, She, Dewei, additional, Wolff, Mark, additional, Zhou, Eric, additional, Makhene, Mamodikoe, additional, Mason, Robin, additional, Sizemore, Christine, additional, and Brennan, Patrick J., additional

Published
2014
Full Text
View/download PDF

36. T-Cell Regulation in Lepromatous Leprosy

Author

Bobosha, Kidist, primary, Wilson, Louis, additional, van Meijgaarden, Krista E., additional, Bekele, Yonas, additional, Zewdie, Martha, additional, van der Ploeg- van Schip, Jolien J., additional, Abebe, Markos, additional, Hussein, Jemal, additional, Khadge, Saraswoti, additional, Neupane, Kapil D., additional, Hagge, Deanna A., additional, Jordanova, Ekaterina S., additional, Aseffa, Abraham, additional, Ottenhoff, Tom H. M., additional, and Geluk, Annemieke, additional

Published
2014
Full Text
View/download PDF

38. Persistent dengue emergence: the 7 years surrounding the 2010 epidemic in Nepal.

Author

Pandey, Basu Dev, Pandey, Kishor, Neupane, Biswas, Shah, Yogendra, Adhikary, Krishna P., Gautam, Ishan, Hagge, Deanna A., and Morita, Kouichi

Subjects
DENGUE, EPIDEMICS, IMMUNOGLOBULIN analysis, EPIDEMIOLOGY, VIRUS diseases
Abstract

Background: Dengue fever (DF) is an emerging public health problem in Nepal, and yet neither the magnitude of the DF burden or its epidemiological trends are well understood. Methods:We conducted a sero-epidemiological, seasonal trend and demographic analysis of the trends in DF in the Terai region of Nepal, from 2007 to 2013. In that period, 2002 serum samples were collected from febrile patients suspected of dengue virus infection. Sampleswere screened by IgM antibody ELISA analysis for the presence of anti-dengue IgM antibodies. Results: The overall prevalence of DF cases was found to range from 26.1 to 55.4%. Infection was found to be more common among adults and males. Seasonal trends revealed that cases peaked in October and November. Conclusions: The study offers perspective on the dengue fever burden before, during and after a major epidemic and can now be used as a basis for formulating strategies by policy makers that will enhance and develop relevant control and preventive measures against dengue fever. The findings of this study reinforce the perceived need for urgent dengue virus surveillance to enhance dengue control strategies that need to be developed for future preparedness. In the light of the recent earthquakes, future major outbreaks of vector borne disease are likely to recur. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

39. Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal

Author

Bobosha, Kidist, primary, Tang, Sheila Tuyet, additional, van der Ploeg-van Schip, Jolien J, additional, Bekele, Yonas, additional, Martins, Marcia VSB, additional, Lund, Ole, additional, Franken, Kees LMC, additional, Khadge, Saraswoti, additional, Pontes, Maria Araci de Andrade, additional, Gonçalves, Heitor de Sá, additional, Hussien, Jemal, additional, Thapa, Pratibha, additional, Kunwar, Chhatra B, additional, Hagge, Deanna A, additional, Aseffa, Abraham, additional, Pessolani, Maria Cristina Vidal, additional, Pereira, Geraldo MB, additional, Ottenhoff, Tom HM, additional, and Geluk, Annemieke, additional

Published
2012
Full Text
View/download PDF

40. Comparison of two rapid tests for anti-phenolic glycolipid-I serology in Brazil and Nepal

Author

Stefani, Mariane Martins de Araújo, primary, Grassi, Adriano Badotti, additional, Sampaio, Lucas Henrique, additional, Sousa, Ana Lúcia Osório Maroclo de, additional, Costa, Maurício Barcelos, additional, Scheelbeek, Pauline, additional, Neupane, Kapil D, additional, Hagge, Deanna A, additional, Macdonald, Murdo, additional, Cho, Sang-Nae, additional, Oskam, Linda, additional, and Bührer-Sékula, Samira, additional

Published
2012
Full Text
View/download PDF

43. A comparison of the change in clinical severity scale score and a retrospective physician assessment of neurological outcome in individuals with leprosy associated nerve function impairment after treatment with corticosteroids

Author

Walker, Stephen L., primary, Nicholls, Peter G., primary, Dhakal, Sushmita, primary, Hawksworth, Rachel A., primary, Macdonald, Murdo, primary, Mahat, Kishori, primary, Ruchal, Shudan, primary, Hamal, Sushma, primary, Hagge, Deanna A., primary, Neupane, Kapid Dev, primary, and Lockwood, Diana N.J., primary

Published
2012
Full Text
View/download PDF

46. A Phase Two Randomised Controlled Double Blind Trial of High Dose Intravenous Methylprednisolone and Oral Prednisolone versus Intravenous Normal Saline and Oral Prednisolone in Individuals with Leprosy Type 1 Reactions and/or Nerve Function Impairment

Author

Walker, Stephen L., primary, Nicholls, Peter G., additional, Dhakal, Sushmita, additional, Hawksworth, Rachel A., additional, Macdonald, Murdo, additional, Mahat, Kishori, additional, Ruchal, Shudan, additional, Hamal, Sushma, additional, Hagge, Deanna A., additional, Neupane, Kapil D., additional, and Lockwood, Diana N. J., additional

Published
2011
Full Text
View/download PDF

48. The lta4h Locus Modulates Susceptibility to Mycobacterial Infection in Zebrafish and Humans

Author

Tobin, David M., primary, Vary, Jay C., additional, Ray, John P., additional, Walsh, Gregory S., additional, Dunstan, Sarah J., additional, Bang, Nguyen D., additional, Hagge, Deanna A., additional, Khadge, Saraswoti, additional, King, Mary-Claire, additional, Hawn, Thomas R., additional, Moens, Cecilia B., additional, and Ramakrishnan, Lalita, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results